Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient is ≥18 years of age at observational point 1~* The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice~* The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care~* The patient must be newly prescribed with certolizumab pegol~* If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study~Exclusion Criteria:~Not applicable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: None): Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).

Based on this trial design, predict the completion outcome and termination type (if applicable).